



UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: France COUTURE et al

RECEIVED  
MAR 27 2002  
TECH CENTER 1600/2900  
642

Serial No. : 10/022,832

Filed : December 20, 2001

For : NOVEL CHLAMYDIA ANTIGENS AND CORRESPONDING DNA  
FRAGMENTS

**INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97**

Assistant Commissioner for Patents  
Washington, D. C. 20231

Sir:

**CITED MATERIALS**

Applicant(s) wish to disclose the following information, listed in the attached form PTO-1449.

- ☐ Copies of materials listed but not attached were cited in parent application Serial No. \_\_\_\_\_.
- ☐ Copies of materials listed but not attached were cited in an International Search Report dated \_\_\_\_\_; receipt of any International Search Report and copies of references were confirmed by the PCT International Division of the U.S. PTO in the Notice of Acceptance mailed \_\_\_\_\_.

Copies of materials listed and attached were cited in a communication from a foreign patent office in a counterpart foreign application.

- ☐ Also included are the pending U.S. applications listed below, copies of which are attached:

**FEES**

- ☒ No fee is required for this Information Disclosure Statement because:
- ☐ This Information Disclosure Statement is being filed within three months of the filing date of a national application (other than a CPA) under § 1.53(d) or within 3 months of the date of entry of the national stage under § 1.491 in an international application;
- ☒ This Information Disclosure Statement is being filed before the mailing of a first action on the merits;
- ☐ This Information Disclosure Statement is being filed before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that closes prosecution in the application, and is accompanied by a certification below.
- ☐ A check is attached: This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a

notice of allowance under § 1.311 or an action that closes prosecution, and is accompanied by the fee set forth in § 1.17(p).

- ☐ A check is attached: This Information Disclosure Statement is being filed after the mailing date of a notice of allowance under § 1.311 but before the payment of the issue fee and is accompanied by the fee set forth in § 1.17(p) and a certification below.


**CERTIFICATION**

- ☐ Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR § 1.56(c), more than three months prior to the filing of this statement.

**DEPOSIT ACCOUNT**

If appropriate, attached is a check in the amount of \$ \_\_\_\_\_. However, the Commissioner is hereby authorized to charge fees under 37 CFR 1.16 and 1.17 which may be required to facilitate this filing, or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,



Brion P. Heaney  
Registration No. 32,542  
Attorney for Applicant(s)

MILLEN, WHITE, ZELANO  
& BRANIGAN, P.C.  
Arlington Courthouse Plaza I  
2200 Clarendon Blvd. Suite 1400  
Arlington, Virginia 22201  
Telephone: (703) 243-6333  
Facsimile: (703) 243-6410

Date: March 25, 2002

MAR 2 5 2002

Please type a plus sign (+) inside this box →

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

2

**Compleat if Kn wn**

Application Number	10/022,832
Filing Date	December 20, 2001
First Named Inventor	France COUTURE et al
Group Art Unit	1642
Examiner Name	Unassigned
Attorney Docket Number	BIOVAC-15

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A1	KORNACKI et al., "Lyme Disease-Causing <i>Borrelia</i> Species Encode Multiple Lipoproteins Homologous to Peptide-Binding Proteins of ABC-Type Transporters", <i>Infection and Immunity</i> , Sept 1998, pp.4115-4122, Vol. 66, No. 9	
	A2	BOREZEE et al., "OppA of <i>Listeria monocytogenes</i> , an Oligopeptide-Binding Protein Required for Bacterial Growth at Low temperature and Involved in Intracellular Survival", <i>Infection and Immunity</i> , Dec 2000, pp. 7069-7077, Vol. 68, No. 12	
	A3	LUNDEMOSE et al., " <i>Chlamydia trachomatis</i> Mip-like protein has peptidylprolyl <i>cis/trans</i> isomerase activity that is inhibited by FK506 and rapamycin and is implicated in initiation of chlamydial infection", <i>Molecular Microbiology</i> , 1993, pp. 777-783, Vol. 7(5)	
	A4	LUNDEMOSE et al., " <i>Chlamydia trachomatis</i> Mip-like protein", <i>Molecular Microbiology</i> , 1992, pp. 2539-2548, Vol. 6(17)	
	A5	ENGLEBERG et al., "DNA Sequence a <i>mip</i> , a <i>Legionella pneumophila</i> Gene Associated with Macrophage Infectivity", <i>Infection and Immunity</i> , Apr 1989, pp.1263-1270, Vol. 57, No. 4	
	A6	CIANCIOOTTO et al., "A <i>Legionella pneumophila</i> Gene Encoding a Species-Specific Surface Protein Potentiates Initiation of Intracellular Infection", <i>Infection and Immunity</i> , Apr. 1989, pp. 1255-1262, Vol. 57, No 4	
	A7	LUNDEMOSE et al., "The <i>Chlamydia trachomatis</i> Mip-like Protein Is a Lipoprotein", <i>Journal of Bacteriology</i> , June 1993, pp. 3669-3671, Vol. 175, No. 11	
	A8	ROCKEY et al., "A 28 kDa major immunogen of <i>Chlamydia psittaci</i> shares identity with Mip proteins of <i>Legionella</i> spp. and <i>Chlamydia trachomatis</i> -cloning and characterization of the <i>C. psittaci</i> <i>mip</i> -like gene", <i>Microbiology</i> , 1996, pp.945-953, Vol. 142	
	A9	RATCLIFF et al., "Interspecies sequence differences in the Mip protein form the genus <i>Legionella</i> : implication for function and evolutionary relatedness", <i>Molecular Microbiology</i> , 1997, pp. 1149-1158, Vol. 25(6)	
	A10	CIANCIOOTTO et al., "A mutation in the <i>mip</i> Gene results in an attenuation of <i>Legionella pneumophila</i> Virulence", <i>The Journal of Infectious Diseases</i> , 1990, pp.121-126, Vol. 162	
	A11	CIANCIOOTTO et al., "Identification of <i>mip</i> -Like Genes in the Genus <i>Legionella</i> ", <i>Infection and Immunity</i> , Sept 1990, pp. 2912-2918, Vol. 58, No. 9	

Examiner  
SignatureDate  
Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+ RECEIVED

Please type plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

### Complete if Known

Application Number	10/022,832
Filing Date	December 20, 2001
First Named Inventor	France COUTURE et al
Group Art Unit	1642
Examiner Name	Unassigned
Attorney Docket Number	BIOVAC-15

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A12	ENGLEBERG et al., "Legionella pneumophila Surface Antigens Cloned and Expressed in Escherichia coli Are translocated to the Host Cell Surface and Interact with Specific Anti-Legionella Antibodies", <u>Journal of Bacteriology</u> , Oct 1984, pp 199-203, Vol. 160, No. 1	
	A13	O'CONNELL et al., "Characterization of Legionella micdadei mip Mutant", <u>Infection and Immunology</u> , Aug 1995, pp. 2840-2845, Vol. 63, No. 8	
	A14	LUNDEMOSE et al., "Chlamydia trachomatis contains a protein similar to the Legionella pneumophila mip gene product", <u>Mol Microbiol</u> , Jan 1991, pp. 109-115, Vol. 5(1)	

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.